Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study - Sorbonne Université Accéder directement au contenu
Article Dans Une Revue Acta Neuropathologica Année : 2019

Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study

Bryan Li
  • Fonction : Auteur
Fupan Yao
  • Fonction : Auteur
Ben Ho
  • Fonction : Auteur
Mei Lu
  • Fonction : Auteur
Eugene Hwang
  • Fonction : Auteur
Sridharan Gururangan
  • Fonction : Auteur
Jordan Hansford
  • Fonction : Auteur
Sumihito Nobusawa
  • Fonction : Auteur
Jason Fangusaro
  • Fonction : Auteur
Helen Toledano
  • Fonction : Auteur
Palma Solano-Paez
  • Fonction : Auteur
Sarah Leary
  • Fonction : Auteur
Diane Birks
  • Fonction : Auteur
Lindsey Hoffman
  • Fonction : Auteur
Xing Fan
  • Fonction : Auteur
Daniel Catchpoole
  • Fonction : Auteur
Li Zhou
  • Fonction : Auteur
Kris Ann P. Schultz
  • Fonction : Auteur
Koichi Ichimura
  • Fonction : Auteur
Nada Jabado
  • Fonction : Auteur
Chris Jones
  • Fonction : Auteur
David Ziegler
  • Fonction : Auteur
Shinya Tanaka
  • Fonction : Auteur
Scott Pomeroy
  • Fonction : Auteur
Amar Gajjar
  • Fonction : Auteur
Vijay Ramaswamy
  • Fonction : Auteur
Cynthia Hawkins
  • Fonction : Auteur
Richard Grundy
  • Fonction : Auteur
D. Ashley Hill
  • Fonction : Auteur
Eric Bouffet
  • Fonction : Auteur
Annie Huang
  • Fonction : Auteur
Anne Jouvet
  • Fonction : Auteur
  • PersonId : 942866

Résumé

Pineoblastomas (PBs) are rare, aggressive pediatric brain tumors of the pineal gland with modest overall survival despite intensive therapy. We sought to define the clinical and molecular spectra of PB to inform new treatment approaches for this orphan cancer. Tumor, blood, and clinical data from 91 patients with PB or supratentorial primitive neuroectodermal tumor (sPNETs/CNS-PNETs), and 2 pineal parenchymal tumors of intermediate differentiation (PPTIDs) were collected from 29 centres in the Rare Brain Tumor Consortium. We used global DNA methylation profiling to define a core group of PB from 72/93 cases, which were delineated into five molecular sub-groups. Copy number, whole exome and targeted sequencing, and miRNA expression analyses were used to evaluate the clinico-pathologic significance of each sub-group. Tumors designated as group 1 and 2 almost exclusively exhibited deleterious homozygous loss-of-function alterations in miRNA biogenesis genes (DICER1, DROSHA, and DGCR8) in 62 and 100% of group 1 and 2 tumors, respectively. Recurrent alterations of the oncogenic MYC-miR-17/92-RB1 pathway were observed in the RB and MYC sub-group, respectively, characterized by RB1 loss with gain of miR-17/92, and recurrent gain or amplification of MYC. PB sub-groups exhibited distinct clinical features: group 1-3 arose in older children (median ages 5.2-14.0 years) and had intermediate to excellent survival (5-year OS of 68.0-100%), while Group RB and MYC PB patients were much younger (median age 1.3-1.4 years) with dismal survival (5-year OS 37.5% and 28.6%, respectively). We identified age < 3 years at diagnosis, metastatic disease, omission of upfront radiation, and chr 16q loss as significant negative prognostic factors across all PBs. Our findings demonstrate that PB exhibits substantial molecular heterogeneity with sub-group-associated clinical phenotypes and survival. In addition to revealing novel biology and therapeutics, molecular sub-grouping of PB can be exploited to reduce treatment intensity for patients with favorable biology tumors.

Dates et versions

hal-04573778 , version 1 (13-05-2024)

Identifiants

Citer

Bryan Li, Alexandre Vasiljevic, Christelle Dufour, Fupan Yao, Ben Ho, et al.. Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. Acta Neuropathologica, 2019, 139 (2), pp.223-241. ⟨10.1007/s00401-019-02111-y⟩. ⟨hal-04573778⟩
4 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More